文献速递中枢神经肿瘤放疗消化道肿瘤放疗泌尿生殖与妇科肿瘤放疗

电子与光子混合超高剂量率与常规剂量率治疗用于将FLASH-RT临床转化至深部靶区:一项治疗计划研究

Hybrid ultra-high and conventional dose rate treatments with electrons and photons for the clinical transfer of FLASH-RT to deep-seated targets: A treatment planning study.
PubMed 文献 · Radiother Oncol · 2024-10-11

本研究通过治疗计划探索混合超高剂量率(UHDR)电子束与常规剂量率(CDR)光子(HUC)放疗治疗深部肿瘤的剂量学可行性及计划质量。针对胶质母细胞瘤、胰腺癌和前列腺癌病例,HUC计划与临床交付计划剂量学质量相当,且相当部分剂量以UHDR递送至PTV及周围组织。胶质母细胞瘤HUC boost场景下评估了FLASH保护效应。

要点

  • HUC计划在三个病例中PTV覆盖(V95%差异在0.5%以内)、均匀性和危及器官保护与临床计划相当。
  • HUC计划将PTV中位剂量50-69%以UHDR递送。
  • 胶质母细胞瘤15 Gy单次UHDR电子boost的FLASH保护场景中,D2%,PTV保护幅度分别为10%和32%。

核心结论

  • 从计划角度看,HUC治疗是递送剂量学适形UHDR治疗的可行方法,可能减轻深部肿瘤适形FLASH-RT的技术挑战。
  • 需要进一步研究针对特定患者队列优化HUC分割和递送方案,HUC治疗为FLASH-RT的临床转化提供了有前景的途径。

研究设计与样本

  • 治疗计划研究,优化宽束UHDR电子束(20-250 MeV)联合CDR VMAT,针对胶质母细胞瘤、胰腺癌和前列腺癌各一例。
  • HUC计划基于临床处方和分割方案,并与临床交付计划进行比较。
  • 胶质母细胞瘤HUC boost治疗由15 Gy单次UHDR电子boost联合VMAT组成,使用FLASH修饰因子加权剂量评估两种FLASH保护场景。

主要发现

  • 三个病例的HUC计划均显示与临床计划相当的剂量学质量,PTV覆盖相似(V95%差异在0.5%以内)、均匀性和关键危及器官保护相似。
  • HUC计划将PTV中位剂量50-69%及周围组织以UHDR递送。
  • 胶质母细胞瘤HUC boost治疗中,第一个FLASH保护场景显示15 Gy UHDR电子boost对D2%,PTV的中等FLASH保护幅度为10%。
  • 第二个场景显示PTV内外脑组织更大幅度的保护:D2%,PTV为32%,D2%,Brain为31%。

局限性

  • 需要进一步研究针对特定患者队列优化HUC分割和递送方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study explores the dosimetric feasibility and plan quality of hybrid ultra-high dose rate (UHDR) electron and conventional dose rate (CDR) photon (HUC) radiotherapy for treating deep-seated tumours with FLASH-RT. METHODS: HUC treatment planning was conducted optimizing a broad UHDR electron beam (between 20-250 MeV) combined with a CDR VMAT for a glioblastoma, a pancreatic cancer, and a prostate cancer case. HUC plans were based on clinical prescription and fractionation schemes and compared against clinically delivered plans. Considering a HUC boost treatment for the glioblastoma consisting of a 15-Gy-single-fraction UHDR electron boost supplemented with VMAT, two scenarios for FLASH sparing were assessed using FLASH-modifying-factor-weighted doses. RESULTS: For all three patient cases, HUC treatment plans demonstrated comparable dosimetric quality to clinical plans, with similar PTV coverage (V95% within 0.5 %), homogeneity, and critical OAR-sparing. At the same time, HUC plans delivered a substantial portion of the dose to the PTV (Dmedian of 50-69 %) and surrounding tissues at UHDR. For the HUC boost treatment of the glioblastoma, the first FLASH sparing scenario showed a moderate FLASH sparing magnitude (10 % for D2%,PTV) for the 15-Gy UHDR electron boost, while the second scenario indicated a more substantial sparing of brain tissues inside and outside the PTV (32 % for D2%,PTV, 31 % for D2%,Brain). CONCLUSIONS: From a planning perspective, HUC treatments represent a feasible approach for delivering dosimetrically conformal UHDR treatments, potentially mitigating technical challenges associated with delivering conformal FLASH-RT for deep-seated tumours. While further research is needed to optimize HUC fractionation and delivery schemes for specific patient cohorts, HUC treatments offer a promising avenue for the clinical transfer of FLASH-RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Böhlen TT, Zeverino M, Germond JF, et al. Hybrid ultra-high and conventional dose rate treatments with electrons and photons for the clinical transfer of FLASH-RT to deep-seated targets: A treatment planning study. Radiother Oncol. 2024. PMID: 39395673. doi:10.1016/j.radonc.2024.110576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。